ArticleCommunications medicine2026
Pretreatment blood NfL indicates response to cellular therapies in cerebral adrenoleukodystrophy.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neuroinflammatory cerebral form of X-linked adrenoleukodystrophy (CALD) is among the most severe neurological diseases affecting children. Early intervention by hematopoietic stem cell transplantation (HSCT) or gene therapy halts CALD, justifying its inclusion in newborn screening programmes. Currently, eligibility for treatment is assessed using MRI-based Loes and neurological scoring; however, grading poorly differentiates advanced stages or atypical lesion patterns. We recently identified blood neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), indicative of axonal and glial damage, as valid biomarkers reflecting CALD activity.
methodsHere, we investigated how pre-treatment biomarker levels relate to outcome of HSCT or gene therapy in a retrospective cohort of 14 paediatric CALD patients aged 5-13 years. Patients were monitored longitudinally before and for up to 5.5 years following HSCT or gene therapy. Disease progression was assessed using MRI-based Loes scoring and neurological evaluations. Plasma NfL and GFAP were quantified using single molecule array (Simoa) technology.
resultsHere we show that blood NfL and GFAP transiently increase due to myeloablative conditioning and gradually normalize post-treatment. Pre-treatment NfL ≤ 113 pg/ml, but not GFAP, correlate with CALD stabilization or, for Loes >9, only minor progression. In contrast, NfL >243 pg/ml associates with major progression irrespective of baseline Loes score. In three boys with atypical lesions or advanced disease, NfL outperforms Loes-scoring in predicting outcome.
conclusionsBlood NfL can complement clinical decision-making, particularly in patients with advanced CALD or atypical lesions. These findings are especially relevant for clinical management in countries that have not yet implemented X-linked adrenoleukodystrophy into newborn screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.